Experimental cell therapy targets Hard-to-Treat ovarian cancers
NCT ID NCT06342986
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new immune cell therapy called FT536 for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The treatment is given directly into the abdomen after a short course of chemotherapy. Only 3 participants are enrolled, so the main goal is to check safety and see if the therapy can slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FT536 (a type of immune cell therapy made from stem cells, given into the abdomen)
What this could lead to
If it works, this could point toward a new treatment option for people with recurrent gynecologic cancers that have not responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 3 participants, so it is too soon to know if it is safe or effective. The treatment also requires chemotherapy beforehand, which has its own side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States